Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
The positive results from this preclinical study underscore Ketamir-2’s potential as a superior alternative to traditional ketamine
Unlike ketamine, which requires intravenous or intranasal administration, Ketamir-2’s oral formulation promises ease of use and better patient compliance and is not a controlled substance under DEA rules